Now showing items 1-3 of 3
Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
BACKGROUND: Alemtuzumab is a CD52-specific monoclonal antibody that markedly depletes T and B lymphocytes and inhibits relapsing multiple sclerosis (MS). However, polymorphonuclear neutrophils also express CD52 and can be ...
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
OBJECTIVE: To evaluate 5-year efficacy and safety of alemtuzumab in patients with active relapsing-remitting multiple sclerosis and inadequate response to prior therapy. METHODS: In the 2-year Comparison of Alemtuzumab and ...
Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.
There are several options for switching people with multiple sclerosis (MS) who are at high risk of developing progressive multifocal leukoencephalopathy (PML) from natalizumab to alemtuzumab. However, some of these have ...